Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
Type 2 drugs could lower dementia, Parkinson's disease risk
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.
Some diabetes meds might lower risk of dementia, Parkinson's
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.
These Diabetes Drugs Could Help Lower Your Risk of Dementia, Parkinson’s
According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood glucose to improve blood sugar levels.
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
Sodium-glucose cotransporter-2 (
SGLT2
) inhibitors, also known as gliflozins, lower blood sugar by prompting the kidneys to filter sugar out of the bloodstream and excrete it in urine, researchers said. But these drugs might also protect brain health ...
Some diabetes medications linked to lower dementia, Parkinson's disease risk
Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By encouraging the kidneys to eliminate sugar from the body through urine, they reduce blood sugar.
SGLT2 inhibitors tied to lower risk of dementia, Parkinson’s disease, suggests study
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson’s disease, according to a study published in the September 18, 2024, online issue of Neurology®,
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology.
Medscape
11d
Do SGLT2 Inhibitors Benefit Everyone With T2D and CKD?
New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...
Daily
10d
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Secret Service admits failure
Accepts CNN debate invite
Russia threatens retaliation
Feds subpoena Schaeffer
Released after guilty plea
WI high court to decide
SC 1st execution in 13 years
Pandas leaving for China
Drug price challenge revived
Boeing defense chief exits
FBI agents board vessel
Sesame Place suit verdict
Hiker injured in bear attack
FDA approves flu vaccine
144K+ Mavericks recalled
Stein's ballot bid rejected
$230 million crypto theft
House repeals emission rules
1st rabies outbreak in seals
Sues pharmacy middlemen
TN abortion law blocked
J&J unit files for bankruptcy
Hand count approved in GA
Top Hezbollah leader killed?
Baby powder recalled
Bill to boost security OK'd
Disney to stop using Slack
In-person voting begins
Beirut strike death toll
Rallies in North Carolina
ISR strike on Gaza school
Related topics
Parkinson's disease
diabetes
Feedback